|
#1
09.10.2008, 15:46
|
|||
|
|||
|
Íîâîñòè/îáçîðû äåðìàòîëîãèè
Ê ñëîâó î "ïîâàëüíîì óâëå÷åíèè" äåðìàòîëîãîâ îòïðàâëÿòü ïàöèåíòîâ íà ïîèñê "äèñáàêòåðèîçà" è ïîñëåäóþùåì íàçíà÷åíèè ïðîáèîòèêîâ(Êîõðàíîâñêèé îáçîð- âûñîêèé óðîâåíü äîêàçàòåëüíîñòè)
"Probiotics for treating eczema" "Ïðîáèîòêè â ëå÷åíèè ýêçåìû"[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "Abstract Background Probiotics have been proposed as an effective treatment for eczema, and recently a number of clinical trials have been undertaken. Objectives To assess the effects of probiotics for the treatment of eczema Search strategy We searched the Cochrane Skin Group Specialised Register (to April 2008), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2,2008) MEDLINE (from 2003 to April 2008), EMBASE (from 2005 to April 2008), PsycINFO, AMED and LILACS (from inception to April 2008) and ISI Web of Science (to December 2006) and reference lists of articles. We also searched registries of ongoing clinical trials, conference proceedings and searched for adverse events. Selection criteria Randomised controlled trials of live orally ingested microorganisms for the treatment of eczema. Data collection and analysis Two authors independently applied eligibility criteria, assessed the quality of trials and extracted data. We contacted study authors for more information where necessary. We recorded adverse events from the included studies, and from the separate adverse events search. Main results Twelve randomised controlled trials involving 781 participants met the inclusion criteria. All trial participants were children. There was no significant difference in participant or parent-rated symptom scores in favour of probiotic treatment (5 trials, 313 participants). Symptom severity on a scale from 0 to20 was 0.90 points lower after probiotic treatment than after placebo (95%CI -1.04, 2.84; p = 0.36).There was also no significant difference in participant or parent-rated overall eczema severity in favour of probiotic treatment (3 trials, 150 participants). There was no significant difference in investigator rated eczema severity between probiotic and placebo treatments (7 trials, 588 participants). On a scale from 0 to 102 investigator rated eczema severity was 2.46 points lower after probiotic treatment than after placebo treatment (95%CI -2.53, 7.45 p = 0.33). Significant heterogeneity was noted between the results of individual studies, which may be explained by the use of different probiotic strains. Subgroup analysis by age of participant, severity of eczema, presence of atopy or presence of food allergy did not identify a population with different treatment outcomes to the population as a whole. The adverse events search identified some case reports of infections and bowel ischaemia caused by probiotics. Authors' conclusions The evidence suggests that probiotics are not an effective treatment for eczema, and probiotic treatment carries a small risk of adverse events." Ïî çàêëþ÷åíèþ àâòîðîâ ïðîáèîòèêè íåýôôåêòèâíû äëÿ ëå÷åíèÿ ýêçåìû, è ëå÷åíèå ïðîáèîòèêàìè íåñ¸ò íåáîëüøîé ðèñê íåáëàãîïðèÿòíûõ ñîáûòèé( èíôåêöèè è èøåìèÿ êèøå÷íèêà) 
|
|
#2
10.10.2008, 01:44
|
|||
|
|||
|
Ðîçîâûé ëèøàé Æèëüáåðà
"Interventions for pityriasis rosea"
"Âìåøàòåëüñòâî ïðè ðîçîâîì ëèøàå" 18 April 2007 in Issue 2, 2007 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Abstract Background Pityriasis rosea is a scaly rash that mainly affects young adults. It can be very itchy but most people recover within 2 to 12 weeks. Objectives To assess the effects of interventions for pityriasis rosea. Search strategy We searched the Cochrane Skin Group Specialised Register (December 2004), the Cochrane Central Register of Controlled Clinical Trials in The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to January 2005), EMBASE (1976 to January 2005), LILACS (1982 to January 2005), BIOSIS Preview (1980 to June 2002), and ongoing trials databases. We scanned bibliographies of published studies, abstracts from dermatology conference proceedings, corresponded with trialists and contacted the pharmaceutical industry. Selection criteria Randomised controlled trials evaluating interventions for pityriasis rosea. Data collection and analysis Two authors independently assessed trial quality and extracted data. We contacted study authors to retrieve missing data. Main results Three trials involving 148 people were included. One poor quality trial (23 people), compared intravenous glycyrrhizin and intravenous procaine. It found no significant difference between the two interventions for treating symptoms and rash. One fair quality trial (85 people), compared the oral antihistamine dexchlorpheniramine (4 mg), the oral steroid betamethasone (500 mcg), and a combination of betamethasone (250 mcg) and dexchlorpheniramine (2 mg). It found no significant difference in itch resolution at two weeks, as rated by the participants, between dexchlorpheniramine and betamethasone, and the combination of dexchlorpheniramine and betamethasone. However, both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash than the combination of dexchlorpheniramine and betamethasone. These interventions were not compared with placebo. The small good quality trial (40 people) that compared oral erythromycin and placebo found that erythromycin was more effective than placebo in terms of rash improvement, as rated by the trialists, after two weeks (RR 13.00; 95% CI 1.91 to 88.64). It was also more effective in decreasing the itch score (difference of 3.95 points, 95% CI 3.37 to 4.53). No serious adverse effects were reported for the interventions. Two out of 17 people on oral erythromycin and 1 out of 17 on placebo reported minor gastrointestinal upset. Authors' conclusions We found inadequate evidence for efficacy for most treatments for pityriasis rosea. Oral erythromycin may be effective in treating the rash and decreasing the itch. However, this result should be treated with caution since it comes from only one small RCT. More research is necessary to evaluate the efficacy of erythromycin and other treatments. Pityriasis rosea is a scaly rash that mostly affects young adults. It is relatively common and affects about 170 out of every 100,000 people in the community each year. The first sign is a patch of scales, usually on the trunk. A generalised eruption then follows and all lesions disappear within 2 to 12 weeks. This review is important because about 50% of people with pityriasis rosea experience moderate to severe itch. It is not known whether the current treatments, which include tablets, creams, and ultra-violet radiation, are useful and whether the benefits outweigh the risk of adverse effects. We found three randomised controlled trials involving 148 participants. One small poor quality trial compared liquorice root with an anaesthetic injected intravenously (23 people), a fair quality trial compared an antihistamine with a steroid taken orally (85 people), and a good quality trial that compared an antibiotic with placebo tablets (40 people). The poor quality trial found no significant difference between liquorice root and anaesthetic for resolving symptoms or rash. The fair quality trial found no significant difference in itch resolution between the antihistamine and the steroid. However the antihistamine and the steroid on their own were both found to be better at clearing rash than a combination of antihistamine and steroid. The small good quality trial found that the oral antibiotic erythromycin was better than placebo in improving the rash and decreasing the amount of itching. No serious adverse effects were reported for any intervention. Two out of 17 people on oral erythromycin and 1 out of 17 people on oral placebo reported minor gastrointestinal upset. We conclude that there is inadequate evidence of efficacy for most treatments but oral erythromycin may be effective in treating the rash and relieving the itch. Limitations of this review include the small number of trials identified, the small number of participants involved, the inadequate methodology of two of the studies, and finding only one small study that reported the clinical benefits of oral erythromycin. Ïî çàêëþ÷åíèþ àâòîðîâ äàííîãî îáçîðà íå íàéäåíî äîñòàòî÷íûõ äîêàçàòåëüñòâ ýôôåêòèâíîñòè äëÿ áîëüøèíñòâà ñïîñîáîâ ëå÷åíèÿ ðîçîâîãî ëèøàÿ. Ïðè¸ì ýðèòðîìèöèíà âíóòðü ìîæåò áûòü ýôôåêòèâåí â îòíîøåíèå ñûïè è óìåíüøåíèåì çóäà. Îäíàêî, ñ ýòèì ðåçóëüòàòîì íóæíî îáðàùàòüñÿ ñ ïðåäîñòåðåæåíèåì, òàê êàê ýòî äàííûå òîëüêî îäíîãî íåáîëüøîãî èññëåäîâàíèÿ. ×òîáû îöåíèòü ýôôåêòèâíîñòü ýðèòðîìèöèíà è äðóãîãî ëå÷åíèÿ íåîáõîäèìû äîïîëíèòåëüíûå èññëåäîâàíèÿ.
|
|
#3
17.10.2008, 02:57
|
|||
|
|||
|
Àòîïè÷åñêèé äåðìàòèò
Íà ôîðóìå óæå èìåþùàÿñÿ èíôîðìàöèÿ:
http://forums.rusmedserv.com/showthread.php?t=24001 + Êîõðàíîâñêèå èññëåäîâàíèÿ ïî àòîïè÷åñêîìó äåðìàòèòó C1 Atopic dermatitis (atopic eczema, childhood eczema) (Cochrane Skin Group) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïðîôèëàêòèêà(îáîñòðåíèé) è ëå÷åíèå: Ïðîôèëàêòèêà - äèåòà (èñêëþ÷åíèå òîëüêî èçâåñòíûõ àëëåðãåíîâ, íåîáõîäèìîñòü äðóãèõ âàðèàíòîâ ïîêà íå îïðåäåëåííà) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - óìåíüøåíèå âîçäåéñòâèÿ àëëåðãåíîâ ïåðåíîñèìûõ ïî âîçäóõó(íàïðèìåð, êëåù äîìàøíåé ïûëè) - èñïîëüçîâàíèå ýìîëåíòîâ - ïðîôèëàêòèêà àñòìû ó äåòåé ñ àòîïè÷åñêèì äåðìàòèòîì(èñïîëüçîâàíèå öåòèðèçèíà) Ëå÷åíèå òîïè÷åñêîå(ìåñòíîå, íàðóæíîå) ëå÷åíèå: - ýìîëåíòû - òîïè÷åñêèå êîðòèêîñòåðîèäû - êîìáèíèðîâàííûå ïðåïàðàòû êîðòèêîñòåðîèä/àíòèáèîòèê - ïèìåêðîëèìóñ, òàêðîëèìóñ - ïðåïàðàòû ä¸ãòÿ - ïðîïèòàííûå áèíòû(äåãîòü, èõòèîë è äð.) è âëàæíûå ïîâÿçêè ñèñòåìíîå ëå÷åíèå: - àíòèãèñòàìèííûå ïðåïàðàòû - ôîòîòåðàïèÿ, ôîòîõèìèîòåðàïèÿ - àçàòèîïðèí - öèêëîñïîðèí Èçó÷àëàñü ýôôåêòèâíîñòü êèòàéñêèõ òðàâ(Zemaphyte) äëÿ ëå÷åíèÿ àòîïè÷åñêîãî äåðìàòèòà. Ïî íåñêîëüêèì èññëåäîâàíèÿì áûëà ïîêàçàííà ýôôåêòèâíîñòü. Îäíàêî ïðåïàðàò áîëüøå íå ïðîèçâîäèòñÿ, è ÷òîáû äîñòîâåðíî ãîâîðèòü îá ýôôåêòèâíîñòè íåîáõîäèìî áîëüøå êà÷åñòâåííûõ èññëåäîâàíèé: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïëàíèðóåòñÿ îáçîð èññëåäîâàíèé äåéñòâèÿ ïðèìóëû âå÷åðíåé(ïðîòîêîëû): [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Êðîìå òîãî, ïðîäîëæàþò èññëåäîâàòüñÿ äðóãèå ïîäõîäû: - ñîêðàùåíèå àëëåðãåíîâ îêðóæàþùåé ñðåäû - òîïè÷åñêàÿ è ñèñòåìíàÿ àíòèìèêðîáíàÿ òåðàïèÿ - äèåòà - ïñèõîëîãè÷åñêèå ïîäõîäû(ãèïíîç, èíâåðñèÿ ïðèâû÷êè) è äð. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#4
15.11.2008, 03:27
|
|||
|
|||
|
Äëÿ äåðìàòîâåíåðîëîãîâ èíôîðìàöèÿ:
(çäåñü ñîáðàííû íàèáîëåå çíà÷èìûå ðåñóðñû) http://forums.rusmedserv.com/showthread.php?t=14103 http://forums.rusmedserv.com/showthread.php?t=14040 Ñòîèò âûäåëèòü èç íàøèõ ðóññêîÿçû÷íûõ(ïîæàëóé, åäèíñòâåííûé ñàéò "êà÷åñòâåííîé äåðìàòîëîãèè" äëÿ âðà÷åé, îñîáåííî ðàçäåë"Áóäíè äåðìàòîëîãà" è "íîâîñòè"; ðåãóëÿðíî ïðîâîäÿòñÿ òåëåìîñòû ïî ñàìûì àêòóàëüíûì òåìàì; òðåáóåòñÿ ðåãèñòðàöèÿ): [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äëÿ òåõ, êòî ìîæåò ïîïàñòü â Ìîñêâó: Öèòàòà:
|
|
#5
08.12.2008, 15:57
|
|||
|
|||
|
Êîíòàãèîçíûé ìîëëþñê
"Interventions for cutaneous molluscum contagiosum"
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "Authors' conclusions No single intervention has been shown to be convincingly effective in treating molluscum contagiosum." "There is not enough evidence to show that any particular treatment is effective for treating molluscum infection. Molluscum contagiosum, in healthy people, is a self-limiting, relatively harmless viral skin infection. It affects mainly children and adolescents. People may seek treatment, however, for social and aesthetic reasons and because of concerns about spreading the disease to others. This review found that many common treatments for molluscum, such as physical destruction, have not been adequately evaluated. Since most lesions will resolve within months without leaving scars, molluscum contagiosum can be left to heal naturally until better evidence on treatment options emerges." Ýôôåêòèâíûõ ìåòîäîâ ëå÷åíèÿ íà äàííîå âðåìÿ íåò. Óäàëåíèå íå ïðåäîòâðàùàåò ïîÿâëåíèå íîâûõ ýëåìåíòîâ.
|
|
#6
03.03.2009, 02:47
|
|||
|
|||
|
Óâàæàåìûå êîëëåãè!
 ÷åòâåðã, 5 ìàðòà 2009 ã., ñîñòîèòñÿ íàø î÷åðåäíîé òåëåìîñò. Òåìà âèäåîêîíôåðåíöèè - "Ñîâðåìåííàÿ ìîäåëü íàðóæíîé òåðàïèè àòîïè÷åñêîãî äåðìàòèòà".  ïðîãðàììå - 8 âûñòóïëåíèé (Ìîñêâà, Ñàíêò-Ïåòåðáóðã, Åêàòåðèíáóðã) è èíòåðàêòèâíàÿ äèñêóññèÿ. Íà÷àëî òåëåìîñòà â 15.00 ïî Ìîñêîâñêîìó âðåìåíè Òðàíñëÿöèþ âèäåîêîíôåðåíöèè ìîæíî áóäåò óâèäåòü ñ 15.00 äî 17.00 ÌÑÊ ïî àäðåñó [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Óæå ñåãîäíÿ Âû ìîæåòå îçíàêîìèòüñÿ ñ ïðîãðàììîé êîíôåðåíöèè è çàäàòü âîïðîñû äîêëàä÷èêàì. Ñ óâàæåíèåì, ðåäàêöèÿ ïîðòàëà Dermatology.ru
|
|
#7
09.04.2009, 13:19
|
|||
|
|||
|
INTERCHARM professional ÌÂÖ "Êðîêóñ Ýêñïî" (Ìîñêâà)
23-25 àïðåëÿ, 2009ã. ° Ìåæäóíàðîäíàÿ âûñòàâêà ïðîôåññèîíàëüíîé êîñìåòèêè è îáîðóäîâàíèÿ äëÿ ñàëîíîâ êðàñîòû23-25 àïðåëÿ, 2009ã. ° Ìåæäóíàðîäíûé êîíãðåññ ïî ïðèêëàäíîé ýñòåòèêå 23-25 àïðåëÿ, 2009ã. ° Ìåæäóíàðîäíàÿ âñòðå÷à ñïà-ñïåöèàëèñòîâ «ÑÏÀ-ÈÍÑÒÈÒÓÒ» 23-25 àïðåëÿ, 2009ã. ° Ìåæäóíàðîäíàÿ êîíôåðåíöèÿ «Ìåíåäæìåíò ñàëîíîâ êðàñîòû» 23-24 àïðåëÿ, 2009ã. ° Øêîëà Íîãòåâîãî ñåðâèñà 23-24 àïðåëÿ, 2009ã. ° Ïðîôåññèîíàëüíûé ôîðóì äëÿ àïòåê è àïòå÷íûõ ñåòåé 23-24 àïðåëÿ, 2009ã. ° Ñåìèíàð "Ïðîôåññèîíàëüíàÿ êîñìåòèêà: òðåíäû, èãðîêè è íîâûå ðåøåíèÿ â óñëîâèÿõ êðèçèñà" 24 àïðåëÿ, 2009ã. ° Ïðàêòè÷åñêèé ñåìèíàð "Àïïàðàòíàÿ äèàãíîñòèêà â êîñìåòîëîãèè è ýñòåòè÷åñêîé ìåäèöèíå" 24 àïðåëÿ, 2009ã. InterCHARM ÌÂÖ "Êðîêóñ Ýêñïî" (Ìîñêâà) 28-31 îêòÿáðÿ, 2009ã. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
|
|
#8
21.07.2009, 02:40
|
|||
|
|||
|
- ïîäðîáíåå î ãåíåòè÷åñêè îáóñëîâëåííûõ íàðóøåíèÿõ ýïèäåðìàëüíîãî áàðüåðà ïðè àòîïè÷åñêîì äåðìàòèòå:
Epidermal Barrier Dysfunction in Atopic Dermatitis [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Journal of Investigative Dermatology (2009) 129, 1892–1908; doi:10.1038/jid.2009.133; published online 4 June 2009 Öèòàòà:
|
|
#9
21.07.2009, 03:44
|
|||
|
|||
|
- â ðóáðèêå æóðíàëà Journal of Investigative Dermatology (2009) 129, 1849–1851. doi:10.1038/jid.2009.166 áûë îïóáëèêîâàí äîêëàä î âñòðå÷å ñïåöèàëèñòîâ ïî âîïðîñàì èììóíîëîãèè è êîæíûõ çàáîëåâàíèé
Immunology and Skin Disease 2009: Frontiers in Cutaneous Immunology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - áûëà ïðåäñòàâëåíà ïîñëåäíÿÿ èíôîðìàöèÿ ïî ïîâîäó ôàêòîðîâ çàùèòû êîæè îò ïàòîãåíîâ: Michael Zasloff (Georgetown University, Washington, DC) ïðåäñòàâèë êðàòêèé îáçîð ïî àíòèìèêðîáíûì ïåïòèäàì (AMPs) - ìàëåíüêèì áåëêàì, ñèíòåçèðóåìûì ýïèòåëèàëüíûìè êëåòêàìè, è îáåñïå÷èâàþùèõ çàùèòó êîæè îò ïàòîãåíîâ. Ðàçíîîáðàçèå íà ðàçíûõ ÷àñòÿõ òåëà ýòèõ ïåïòèäîâ îòðàæàåò îòëè÷èå ìèêðîáíîé ôëîðû íà ýòèõ ó÷àñòêàõ êîæè. Âèòàìèí Ä ñòèìóëèðóåò ñèíòåç AMP LL-37, ÷òî óâåëè÷èâàåò ôóíêöèîíàëüíóþ ñïîñîáíîñòü ìàêðîôàãîâ. Íåäîñòàòî÷íûé èëè èçáûòî÷íûé ñèíòåç ÀÌÐ àññîöèèðóåòñÿ ñ çàáîëåâàíèÿìè ÷åëîâåêà. Ïàöèåíòû ñ àòîïè÷åñêèì äåðìàòèòîì èìåþò ïîíèæåííîå êîëè÷åñòâî ÀÌÐ è ÷àñòûå êîæíûå èíôåêöèè(îñëîæíåíèå ÀÄ). Ïåðåèçáûòîê ÀÌÐ èìååòñÿ ïðè ïñîðèàçå. Georg Stingl (Medical University of Vienna, Austria) îïèñàë òèïû àíòèãåí-ïðåçåíòèðóþùèõ êëåòîê (APCs), èõ ðîëü â èíèöèèðîâàíèè Ò-êëåòî÷íîãî îòâåòà, îñâåòèë äðóãèå àñïåêòû, êîòîðûå ìîãóò èìåòü îòíîøåíèå ê âîñïàëèòåëüíûì, îíêî-çàáîëåâàíèÿì êîæè, êëåòî÷íîìó àïîïòîçó ïðè HIV èíôåêöèè. Michael Schön (Georg August University, Germany) ïîêàçûâàë ïîðàçèòåëüíûå ôîòîãðàôèè èç êîæíûõ ìåòîñòàç ìåëàíîìû ïîñëå òåðàïèè èìèêâèìîäîì. Ðå÷ü øëà î ðîëè âèòàìèíà Ä â èììóííûõ îòâåòàõ, ðåòèíîåâîé êèñëîòû(âèòàìèíà À), ãåíåòè÷åñêîé êàðòîãðàôèè(âîñïðèèì÷èâîñòü ê ðàêó êîæè) è ò.ä. Áûëè îñâåùåíû ñëîæíûå è àêòóàëüíûå âîïðîñû ñîâðåìåííîé èññëåäîâàòåëüñêîé äåðìàòîëîãèè.
|
|
#10
17.02.2010, 13:24
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Predicting Migraine Responsiveness to Botulinum Toxin Type A Injections - èíúåêöèè áîòîêñà ýôôåêòèâíû â îòíîøåíèå îïðåäåëåííûõ âèäîâ ìèãðåíè Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - ðåêîìåíäóåòñÿ ïðèåì àöèêëîâèðà ïàöèåíòàì ñ ÂÈ×, èìåþùèì ÷àñòûå ðåöèäèâû ãåíèòàëüíîãî ãåðïåñà(îñîáåííî êàñàåòñÿ "íå î÷åíü ðàçâèòûõ ñòðàí"))) : "Efforts should be stepped up to ensure that HIV-infected patients in low-income and middle-income countries who have frequent recurrences of genital herpes or severe genital herpes receive suppressive therapy with acyclovir, as recommended in industrialized countries," write the authors of an accompanying editorial.
|
|
#11
05.10.2010, 17:40
|
|||
|
|||
|
Àòîïè÷åñêèé äåðìàòèò: êîøêè/ñîáàêè
Opposing Effects of Cat and Dog Ownership and Allergic Sensitization on Eczema in an Atopic Birth Cohort
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Conclusion: Dog ownership significantly reduced the risk for eczema at age 4 years among dog-sensitized children, cat ownership combined with cat sensitization significantly increased the risk. - èíòåðåñíûå ðåçóëüòàòû: ñîáàêà â äîìå(ñ ìëàäåí÷åñòâà)-ðèñê ÀÄ íèæå ó äåòåé ñ ñîîòâåòñòâåííîé ÷óâñòâèòåëüíîñòüþ îò ðîæäåíèÿ äî 4 ëåò, êîò-âûøå
|
|
#12
16.11.2010, 21:49
|
|||
|
|||
|
- çàâòðà òåëåìîñò îáùåñòâà äåðìàòîñêîïèè:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#13
30.11.2010, 18:50
|
|||
|
|||
|
II ÍÏÊ "Ñîâðåìåííûå àñïåêòû äåðìàòîâåíåðîëîãèè"
Âòîðàÿ Íàó÷íî-ïðàêòè÷åñêàÿ êîíôåðåíöèÿ «Ñîâðåìåííûå àñïåêòû äåðìàòîâåíåðîëîãèè» áóäåò ïðîâîäèòüñÿ â ã. Ìîñêâå 2– 3 äåêàáðÿ 2010 ãîäà. ÍÏÊ îðãàíèçîâàíà ÔÃÎÓ Èíñòèòóò ïîâûøåíèÿ êâàëèôèêàöèè ÔÌÁÀ Ðîññèè. Êîíôåðåíöèÿ ñîñòîèòñÿ ïî àäðåñó: Ìîñêâà, Ìåæäóíàðîäíûé Âûñòàâî÷íûé Öåíòð "Êðîêóñ Ýêñïî", ïàâèëüîí 2, 1 ýòàæ, ïðîåçä ì. Ìÿêèíèíî.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#14
11.01.2011, 23:16
|
|||
|
|||
|
Óâàæàåìûå êîëëåãè! Êîíêóðñ-"ñëó÷àé ìåñÿöà"!
Óâàæàåìûå êîëëåãè, çäðàâñòâóéòå!
â íàñòóïèâøåì 2011 ãîäó ìû íà÷èíàåì íàø êîíêóðñ êëèíè÷åñêèõ íàáëþäåíèé "Ñëó÷àé ìåñÿöà". Ê ó÷àñòèþ â êîíêóðñå ïðèãëàøàþòñÿ äåðìàòîëîãè Ðîññèè è ñòðàí ÑÍÃ. Íà êîíêóðñ ïðèíèìàþòñÿ îðèãèíàëüíûå êëèíè÷åñêèå íàáëþäåíèÿ, ðàíåå íå îïóáëèêîâàííûå â ìåäèöèíñêîé ëèòåðàòóðå. ×òîáû äîáàâèòü ñâîå íàáëþäåíèå, èñïîëüçóéòå ôîðìó-ññûëêó [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ôîðìàò ðàçìåùåíèÿ îïèñàíèé - ñâîáîäíûé, íåîáõîäèìûì óñëîâèåì ÿâëÿåòñÿ àííîòàöèÿ ïîëåé óêàçàííîé ôîðìû. Ñëó÷àé äîëæåí èìåòü óñòàíîâëåííûé äèàãíîç, íàáëþäåíèÿ pro diagnosi íà êîíêóðñ íå ïðèíèìàþòñÿ. ×òîáû âêëþ÷èòü äîáàâëåííîå Âàìè íàáëþäåíèå â êîíêóðñ, ïîìåòüòå ñïåöèàëüíîå ïîëå âíèçó óêàçàííîé ôîðìû. Îò îäíîãî ïîëüçîâàòåëÿ ìîæåò áûòü íàïðàâëåíî íåñêîëüêî íàáëþäåíèé íà îäèí è òîò æå ýòàï êîíêóðñà. Ïîáåäèòåëü êîíêóðñà - Ñëó÷àé ìåñÿöà - áóäåò îïðåäåëåí â êîíöå ìåñÿöà ãîëîñîâàíèåì ïîñåòèòåëåé ñàéòà. Ïðèçàìè ïîáåäèòåëþ áóäóò öåííûå èçäàíèÿ - êíèãè ïî äåðìàòîëîãèè. Êàæäûé ìåñÿö áóäåò íîâûé ïðèç, à â êîíöå ãîäà áóäåò ïðîâåäåíî ãîëîñîâàíèå ïî ëó÷øåìó ñëó÷àþ ãîäà, è âûèãðàâøåìó äîñòàíåòñÿ åùå îäèí, ñïåöèàëüíûé ïðèç. Èòàê, ìû îáúÿâëÿåì íà÷àëî êîíêóðñà.  ÿíâàðå 2011 ã. êîíêóðñ íà÷èíàåòñÿ íå ñ 1, à ñ 11 ÿíâàðÿ, à ïðèçîì ÿâëÿåòñÿ êíèãà "Äåðìàòîîíêîëîãèÿ" (Ì., 2005, 872 ñ.). Îêîí÷àíèå êîíêóðñà - 1 ôåâðàëÿ 2011 ã. Ñ óâàæåíèåì, ïðîô. Ñåðãååâ À.Þ. X Ìåæäóíàðîäíàÿ âûñòàâêà äëÿ ïðîôåññèîíàëîâ èíäóñòðèè êðàñîòû «KOSMETIK EXPO» 9-12 ôåâðàëÿ 2011 ãîäàÌîñêâà, Ãîñòèíûé äâîð (Èëüèíêà, 4)
|
|
#15
07.11.2013, 19:20
|
||||
|
||||
|
Ñêèí-êàï, íàêîíåö-òî âñÿ ïðàâäà î íåì:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (ëþáåçíî ïðåäîñòàâëåíî nastassia).
|
Ëèíåéíûé âèä
